Acadia (Acad) 2025 Earnings: A Detailed Investor Look
A clear, reader-friendly breakdown of Acadia’s Q4 2025 earnings. We unpack revenue trends, pipeline progress, and key...
Biotech
Biotech insights await. This page curates 5 articles on Tempus, Moderna, Praxis, ImmunityBio and market moves to help you evaluate stocks and sharpen your portfolio strategy.
88 articles
Structure Therapeutics Stock Soars: Key Moves and Outlook
Structure Therapeutics stock has surged after a major hedge fund increased its stake. This article breaks down what s...
Lilly Just Took Major Steps Forward in Obesity Drug Market
Two bold moves by Eli Lilly are reshaping the billion-dollar obesity drug market. This guide breaks down what happene...
Recursion (RXRX) 2025 Earnings: Deep Dive Into Strategy
As biotech investors digest Recursion's latest quarterly results, this Deep Dive breaks down what recursion (rxrx) 20...
Iovance Surged This Week on Philadelphia Factory Backbone
Iovance surged this week after robust Q4 results and a Philadelphia manufacturing moat highlighted by a 32 day turnar...
Alphatec (ATEC) 2025 Earnings Outlook and Q4 Review
Alphatec (ATEC) is navigating a shifting spine device market. This guide breaks down expected 2025 earnings, key driv...
Myriad Genetics (MYGN) 2025 Outlook: Investing Framework
Dive into how to read myriad genetics (mygn) 2025 earnings transcripts, spot growth drivers, assess risk, and build a...
Madrigal (MDGL) 2025 Earnings: What Investors Should Know
As Madrigal prepares to report its 2025 earnings, investors weigh pipeline progress, cash runway, and milestones ahea...
Biotech Investor Adds Million as Krystal Biotech Revenue Rises
A major biotech investor is stepping up its bet on Krystal Biotech as the company posts robust 2025 revenue. This mov...
Using Saliva Detect Disease Faces Billing and Access Hurdles
Saliva-based tests promise easy disease detection, but coverage gaps and costs could slow adoption. Here’s how it cou...
Orbimed Advisors Trims $125 After Breakout Year in Biotech
A major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
Praxis Medicines 2025 Earnings: Key Investor Insights
As earnings season arrives, praxis medicines 2025 earnings offer a compelling snapshot of where the company stands. T...